Understand what this means: https://bit.ly/4jG1I7c
Radicava and Radicava ORS are entering a new phase of management, with plans focused on keeping access stable for people living with ALS.
#ALS #AmyotrophicLateralSclerosis #ALSTreatment #RareDisease #RareDiseaseNews #ALSNewsToday #Bionews
Radicava and Radicava ORS are entering a new phase of management, with plans focused on keeping access stable for people living with ALS.
#ALS #AmyotrophicLateralSclerosis #ALSTreatment #RareDisease #RareDiseaseNews #ALSNewsToday #Bionews
January 12, 2026 at 10:02 PM
Understand what this means: https://bit.ly/4jG1I7c
Radicava and Radicava ORS are entering a new phase of management, with plans focused on keeping access stable for people living with ALS.
#ALS #AmyotrophicLateralSclerosis #ALSTreatment #RareDisease #RareDiseaseNews #ALSNewsToday #Bionews
Radicava and Radicava ORS are entering a new phase of management, with plans focused on keeping access stable for people living with ALS.
#ALS #AmyotrophicLateralSclerosis #ALSTreatment #RareDisease #RareDiseaseNews #ALSNewsToday #Bionews
New ALS research: https://bit.ly/4qg1JkM
APRTX-003 is an experimental RNA based therapy designed to reduce MMP 9, an enzyme associated with nerve cell damage.
#ALSNewsToday #ALSResearch #ALSScience #NeurodegenerativeDisease #RareDiseaseNews #Bionews
APRTX-003 is an experimental RNA based therapy designed to reduce MMP 9, an enzyme associated with nerve cell damage.
#ALSNewsToday #ALSResearch #ALSScience #NeurodegenerativeDisease #RareDiseaseNews #Bionews
January 9, 2026 at 8:02 PM
New ALS research: https://bit.ly/4qg1JkM
APRTX-003 is an experimental RNA based therapy designed to reduce MMP 9, an enzyme associated with nerve cell damage.
#ALSNewsToday #ALSResearch #ALSScience #NeurodegenerativeDisease #RareDiseaseNews #Bionews
APRTX-003 is an experimental RNA based therapy designed to reduce MMP 9, an enzyme associated with nerve cell damage.
#ALSNewsToday #ALSResearch #ALSScience #NeurodegenerativeDisease #RareDiseaseNews #Bionews
Year in review: https://bit.ly/3YbmstE
From major treatment approvals to research that pushed understanding of MG forward, these were the most read Myasthenia Gravis News stories of 2025.
#MyastheniaGravis #MyastheniaGravisNews #MGResearch #ClinicalTrials #MGCommunity #RareDiseaseNews #Bionews
From major treatment approvals to research that pushed understanding of MG forward, these were the most read Myasthenia Gravis News stories of 2025.
#MyastheniaGravis #MyastheniaGravisNews #MGResearch #ClinicalTrials #MGCommunity #RareDiseaseNews #Bionews
December 29, 2025 at 2:03 PM
Year in review: https://bit.ly/3YbmstE
From major treatment approvals to research that pushed understanding of MG forward, these were the most read Myasthenia Gravis News stories of 2025.
#MyastheniaGravis #MyastheniaGravisNews #MGResearch #ClinicalTrials #MGCommunity #RareDiseaseNews #Bionews
From major treatment approvals to research that pushed understanding of MG forward, these were the most read Myasthenia Gravis News stories of 2025.
#MyastheniaGravis #MyastheniaGravisNews #MGResearch #ClinicalTrials #MGCommunity #RareDiseaseNews #Bionews